MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1547 participants.
Also called NCT01154036
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,547 participants
- Sponsor
- Registry
-
NCT01154036
-
- Other papers using this trial's data
- Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia
- Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01154036. Randomized; double masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2012-09 (actual). Results posted on 2014-02-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- ezetimibe 10 mg
- Intervention (Drug)
- atorvastatin
- Intervention (Drug)
- Comparator: rosuvastatin
- Lead sponsor
- Organon and Co
Record details
- Record id
cardio:ct-nct01154036- Content hash
52a87758bccc2713612cb00a9198874d22479174f0a49ab429ba5925a4d4e6f5